Gilead Sciences Statistics
Total Valuation
Gilead Sciences has a market cap or net worth of ARS 257.97 trillion. The enterprise value is 276.02 trillion.
| Market Cap | 257.97T |
| Enterprise Value | 276.02T |
Important Dates
The last earnings date was Tuesday, February 10, 2026.
| Earnings Date | Feb 10, 2026 |
| Ex-Dividend Date | Dec 15, 2025 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.08% |
| Owned by Insiders (%) | 0.10% |
| Owned by Institutions (%) | 89.31% |
| Float | 1.24B |
Valuation Ratios
The trailing PE ratio is 20.89 and the forward PE ratio is 16.99.
| PE Ratio | 20.89 |
| Forward PE | 16.99 |
| PS Ratio | 6.04 |
| PB Ratio | 7.86 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 18.80 |
| P/OCF Ratio | 17.74 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.35, with an EV/FCF ratio of 20.11.
| EV / Earnings | 22.35 |
| EV / Sales | 6.69 |
| EV / EBITDA | 13.35 |
| EV / EBIT | 16.66 |
| EV / FCF | 20.11 |
Financial Position
The company has a current ratio of 1.55, with a Debt / Equity ratio of 1.13.
| Current Ratio | 1.55 |
| Quick Ratio | 1.23 |
| Debt / Equity | 1.13 |
| Debt / EBITDA | 1.73 |
| Debt / FCF | 2.70 |
| Interest Coverage | 11.54 |
Financial Efficiency
Return on equity (ROE) is 40.66% and return on invested capital (ROIC) is 26.86%.
| Return on Equity (ROE) | 40.66% |
| Return on Assets (ROA) | 12.52% |
| Return on Invested Capital (ROIC) | 26.86% |
| Return on Capital Employed (ROCE) | 25.03% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 2.51B |
| Profits Per Employee | 726.55M |
| Employee Count | 17,000 |
| Asset Turnover | 0.50 |
| Inventory Turnover | 3.58 |
Taxes
In the past 12 months, Gilead Sciences has paid 1.87 trillion in taxes.
| Income Tax | 1.87T |
| Effective Tax Rate | 13.13% |
Stock Price Statistics
The stock price has increased by +55.71% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +55.71% |
| 50-Day Moving Average | 51,105.50 |
| 200-Day Moving Average | 42,383.63 |
| Relative Strength Index (RSI) | 53.73 |
| Average Volume (20 Days) | 530 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.91 |
Income Statement
In the last 12 months, Gilead Sciences had revenue of ARS 42.73 trillion and earned 12.35 trillion in profits. Earnings per share was 9,840.49.
| Revenue | 42.73T |
| Gross Profit | 33.69T |
| Operating Income | 17.15T |
| Pretax Income | 14.22T |
| Net Income | 12.35T |
| EBITDA | 21.16T |
| EBIT | 17.15T |
| Earnings Per Share (EPS) | 9,840.49 |
Balance Sheet
The company has 13.95 trillion in cash and 37.07 trillion in debt, giving a net cash position of -18,801.44 billion.
| Cash & Cash Equivalents | 13.95T |
| Total Debt | 37.07T |
| Net Cash | -18,801.44B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 32.83T |
| Book Value Per Share | 26,550.91 |
| Working Capital | 9.48T |
Cash Flow
In the last 12 months, operating cash flow was 14.54 trillion and capital expenditures -817.14 billion, giving a free cash flow of 13.72 trillion.
| Operating Cash Flow | 14.54T |
| Capital Expenditures | -817.14B |
| Free Cash Flow | 13.72T |
| FCF Per Share | n/a |
Margins
Gross margin is 78.84%, with operating and profit margins of 40.14% and 28.90%.
| Gross Margin | 78.84% |
| Operating Margin | 40.14% |
| Pretax Margin | 33.27% |
| Profit Margin | 28.90% |
| EBITDA Margin | 49.51% |
| EBIT Margin | 40.14% |
| FCF Margin | 32.12% |
Dividends & Yields
This stock pays an annual dividend of 641.73, which amounts to a dividend yield of 1.21%.
| Dividend Per Share | 641.73 |
| Dividend Yield | 1.21% |
| Dividend Growth (YoY) | 41.41% |
| Years of Dividend Growth | 7 |
| Payout Ratio | 6.52% |
| Buyback Yield | 0.24% |
| Shareholder Yield | 1.42% |
| Earnings Yield | 4.79% |
| FCF Yield | 5.32% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Gilead Sciences has an Altman Z-Score of 3.9 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.9 |
| Piotroski F-Score | 7 |